Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: SynAct Pharma's CSO comments approved IND and Q3

SynAct Pharma

SynAct Pharma has received IND approval from the FDA, meaning that they can initiate the phase IIa/b RESOLVE study of AP1189 in DMARD-IR patients. They have also just published their report for the third quarter, a busy period with significant progress in the development programmes with AP1189. CSO Thomas Jonassen visited BioStock's studio to talk about the IND approval, patient recruitment in the EXPAND study, financing, and partnering discussions. 

Watch the interview with SynAct Pharma's CSO Thomas Jonassen at biostock.se:

https://www.biostock.se/en/2022/11/synact-pharmas-cso-comments-approved-ind-and-q3

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team